Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLN-081 for EGFR Exon 20 Insertion Mutant NSCLC (Japan Phase 1/2)
jRCT2041230017Phase 2Active, not recruiting
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jul 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of zipalertinib in non-small cell lung cancer (NSCLC), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Objective Response Rate (ORR) and Duration of Response (DOR). Started Jul 2023; status: active, not recruiting.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2041230017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230017.